GFI1 is required for positive acute myeloid leukemia.
作者信息
Marneth Anna E, Botezatu Lacramioara, Hönes Judith M, Israël Jimmy C L, Schütte Judith, Vassen Lothar, Lams Robert F, Bergevoet Saskia M, Groothuis Laura, Mandoli Amit, Martens Joost H A, Huls Gerwin, Jansen Joop H, Dührsen Ulrich, Berg Tobias, Möröy Tarik, Wichmann Christian, Lo Mia-Chia, Zhang Dong-Er, van der Reijden Bert A, Khandanpour Cyrus
机构信息
Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Germany.
出版信息
Haematologica. 2018 Sep;103(9):e395-e399. doi: 10.3324/haematol.2017.180844. Epub 2018 Apr 19.
Abstract
摘要
相似文献
1
GFI1 is required for positive acute myeloid leukemia.GFI1是阳性急性髓性白血病所必需的。
Haematologica. 2018 Sep;103(9):e395-e399. doi: 10.3324/haematol.2017.180844. Epub 2018 Apr 19.
2
ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.ZBTB7A 突变与 t(8;21)易位相关的急性髓系白血病。
Nat Commun. 2016 Jun 2;7:11733. doi: 10.1038/ncomms11733.
3
Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.用AML1-ETO治疗初发急性髓系白血病后AML1-ETO与PML-RARa的共表达
Leuk Lymphoma. 2019 May;60(5):1316-1319. doi: 10.1080/10428194.2018.1520991. Epub 2018 Oct 17.
4
MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.MEIS2 是 AML1-ETO 阳性 AML 的致癌伙伴。
Cell Rep. 2016 Jul 12;16(2):498-507. doi: 10.1016/j.celrep.2016.05.094. Epub 2016 Jun 23.
5
Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.RUNX1/ETO 融合蛋白模块驱动 CD34+ 人祖细胞扩增的兼容性。
Oncogene. 2019 Jan;38(2):261-272. doi: 10.1038/s41388-018-0441-7. Epub 2018 Aug 9.
6
The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.在急性髓系白血病细胞中，t(8;21)融合蛋白RUNX1-ETO下调丙酮酸激酶M2（PKM2）。
Leuk Lymphoma. 2017 Aug;58(8):1985-1988. doi: 10.1080/10428194.2016.1272690. Epub 2017 Jan 16.
7
Definition of a small core transcriptional circuit regulated by AML1-ETO.AML1-ETO 调控的小核心转录回路的定义。
Mol Cell. 2021 Feb 4;81(3):530-545.e5. doi: 10.1016/j.molcel.2020.12.005. Epub 2020 Dec 30.
8
RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.RUNX1-ETO 缺失导致 t(8;21) AML 中增强子-启动子相互作用发生 C/EBPα 和 AP-1 介导的改变。
Cell Rep. 2019 Sep 17;28(12):3022-3031.e7. doi: 10.1016/j.celrep.2019.08.040.
9
The RUNX1/RUNX1T1 network: translating insights into therapeutic options.RUNX1/RUNX1T1 网络：将见解转化为治疗选择。
Exp Hematol. 2021 Feb;94:1-10. doi: 10.1016/j.exphem.2020.11.005. Epub 2020 Nov 17.
10
ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells.ZBTB7A 抑制 RUNX1-RUNX1T1 依赖性人造血干/祖细胞的克隆性扩增。
Oncogene. 2020 Apr;39(15):3195-3205. doi: 10.1038/s41388-020-1209-4. Epub 2020 Mar 2.
引用本文的文献
1
CoREST in pieces: Dismantling the CoREST complex for cancer therapy and beyond.CoREST分解：为癌症治疗及其他领域拆解CoREST复合物
Sci Adv. 2025 Jun 6;11(23):eads6556. doi: 10.1126/sciadv.ads6556.
2
Germline Single-Nucleotide Polymorphism Causes Alterations in Mitochondrial Metabolism and Leads to Increased ROS-Mediated DNA Damage in a Murine Model of Human Acute Myeloid Leukemia.种系单核苷酸多态性导致线粒体代谢改变，并在人类急性髓系白血病小鼠模型中导致活性氧介导的DNA损伤增加。
Biomedicines. 2025 Jan 5;13(1):107. doi: 10.3390/biomedicines13010107.
3
Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML.失调的先天免疫信号传导与RUNX1突变协同作用，将类似骨髓增生异常综合征的疾病转化为急性髓系白血病。
iScience. 2024 Apr 24;27(6):109809. doi: 10.1016/j.isci.2024.109809. eCollection 2024 Jun 21.
4
Understanding blood development and leukemia using sequencing-based technologies and human cell systems.利用基于测序的技术和人类细胞系统来理解血液发育和白血病。
Front Mol Biosci. 2023 Oct 10;10:1266697. doi: 10.3389/fmolb.2023.1266697. eCollection 2023.
5
HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block.HMG20B 通过稳定 LSD1 与染色质上的 GFI1 的结合来发挥作用，从而抑制转录并阻止白血病细胞分化。
Oncogene. 2022 Oct;41(44):4841-4854. doi: 10.1038/s41388-022-02471-y. Epub 2022 Sep 28.
6
Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma.多发性骨髓瘤中恶性浆细胞与肿瘤微环境之间的表观遗传串扰
Cancers (Basel). 2022 May 24;14(11):2597. doi: 10.3390/cancers14112597.
7
GFI1-Dependent Repression of Increases Multiple Myeloma Cell Survival.GFI1 依赖性抑制作用增强多发性骨髓瘤细胞的存活能力。
Cancers (Basel). 2022 Feb 2;14(3):772. doi: 10.3390/cancers14030772.
8
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.AML1/ETO 及其作为通过表观遗传机制调节基因转录的功能。
Oncogene. 2021 Sep;40(38):5665-5676. doi: 10.1038/s41388-021-01952-w. Epub 2021 Jul 30.
9
Multifaceted Actions of GFI1 and GFI1B in Hematopoietic Stem Cell Self-Renewal and Lineage Commitment.GFI1和GFI1B在造血干细胞自我更新和谱系定向中的多方面作用
Front Genet. 2020 Oct 26;11:591099. doi: 10.3389/fgene.2020.591099. eCollection 2020.
10
A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.PML/RARα 直接靶标图谱重新定义了急性早幼粒细胞白血病中的转录失调。
Blood. 2021 Mar 18;137(11):1503-1516. doi: 10.1182/blood.2020005698.
本文引用的文献
1
A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.一个由FOXO1诱导的致癌网络定义了AML1-ETO白血病前期程序。
Blood. 2017 Sep 7;130(10):1213-1222. doi: 10.1182/blood-2016-11-750976. Epub 2017 Jul 14.
2
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.初发复发时的核心结合因子急性髓系白血病：法国 AML 协作组的一项回顾性研究。
Blood. 2014 Aug 21;124(8):1312-9. doi: 10.1182/blood-2014-01-549212. Epub 2014 Jul 8.
3
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.成人新发急性髓系白血病的基因组和表观基因组图谱。
N Engl J Med. 2013 May 30;368(22):2059-74. doi: 10.1056/NEJMoa1301689. Epub 2013 May 1.
4
Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia.生长因子独立性 1 拮抗淋巴母细胞白血病中 p53 诱导的 DNA 损伤反应途径。
Cancer Cell. 2013 Feb 11;23(2):200-14. doi: 10.1016/j.ccr.2013.01.011.
5
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.ERG 和 FLI1 结合位点标志着 AML1-ETO 在急性髓系白血病中异常表观遗传调控的靶标。
Blood. 2012 Nov 8;120(19):4038-48. doi: 10.1182/blood-2012-05-429050. Epub 2012 Sep 14.
6
Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.t(8;21)AML 细胞中 RUNX1/ETO 的耗竭导致染色质结构和转录因子结合的全基因组变化。
Leukemia. 2012 Aug;26(8):1829-41. doi: 10.1038/leu.2012.49. Epub 2012 Feb 20.
7
Gfi1-cells and circuits: unraveling transcriptional networks of development and disease.Gfi1 细胞和回路：揭示发育和疾病的转录网络。
Curr Opin Hematol. 2010 Jul;17(4):300-7. doi: 10.1097/MOH.0b013e32833a06f8.
8
Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.二聚体-四聚体转变控制 RUNX1/ETO 白血病发病机制。
Blood. 2010 Jul 29;116(4):603-13. doi: 10.1182/blood-2009-10-248047. Epub 2010 Apr 29.
9
Gfi1 integrates progenitor versus granulocytic transcriptional programming.Gfi1整合祖细胞与粒细胞转录程序。
Blood. 2009 May 28;113(22):5466-75. doi: 10.1182/blood-2008-09-179747. Epub 2009 Apr 3.
10
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.双CEBPA突变而非单CEBPA突变定义了急性髓系白血病的一个亚组，该亚组具有独特的基因表达谱，且与良好预后唯一相关。
Blood. 2009 Mar 26;113(13):3088-91. doi: 10.1182/blood-2008-09-179895. Epub 2009 Jan 26.
Zotero 插件